WO1999032494A1
(en)
*
|
1997-12-19 |
1999-07-01 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
EP1140945B1
(en)
*
|
1998-12-18 |
2003-06-04 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
US6329367B1
(en)
|
1998-12-18 |
2001-12-11 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
WO2001002410A1
(en)
*
|
1999-06-30 |
2001-01-11 |
Novo Nordisk A/S |
Novel process
|
AU2001265840A1
(en)
*
|
2000-06-26 |
2002-01-08 |
Novo-Nordisk A/S |
Use of potassium channel agonists for reducing fat food comsumption
|
AU2002216097B2
(en)
|
2000-12-21 |
2006-09-07 |
Sanofi-Aventis Deutschland Gmbh |
Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
|
PL362512A1
(en)
|
2000-12-21 |
2004-11-02 |
Avantis Pharma Deutschland Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
WO2002050085A1
(en)
*
|
2000-12-21 |
2002-06-27 |
Novo Nordisk A/S |
A new process for preparing fused 1,2,4-thiadiazine derivatives
|
DE10110747A1
(en)
|
2001-03-07 |
2002-09-12 |
Bayer Ag |
Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use
|
DE10142660A1
(en)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Use of derivatives of C2-substituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity
|
PE20021091A1
(en)
|
2001-05-25 |
2003-02-04 |
Aventis Pharma Gmbh |
DERIVATIVES OF PHENYLUREA SUBSTITUTED WITH CARBONAMIDE AND PROCEDURE FOR THEIR PREPARATION
|
PL366851A1
(en)
|
2001-08-22 |
2005-02-07 |
Aventis Pharma Deutschland Gmbh |
Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
|
DE10142661B4
(en)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
Poly-substituted indan-1-ol systems and their use as pharmaceuticals
|
DE10142665B4
(en)
|
2001-08-31 |
2004-05-06 |
Aventis Pharma Deutschland Gmbh |
C2-Disubstituted indan-1-ones and their derivatives
|
DE10142722A1
(en)
|
2001-08-31 |
2003-03-27 |
Aventis Pharma Deutschland GmbH, 65929 Frankfurt |
C2-substituted indan-1-ones and their derivatives, processes for their preparation and their use as medicaments
|
DE10142667B4
(en)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
C2-substituted indan-1-oles and their derivatives and their use as medicines
|
PT1425014E
(en)
|
2001-08-31 |
2007-03-30 |
Sanofi Aventis Deutschland |
Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
|
US7399777B2
(en)
|
2001-08-31 |
2008-07-15 |
Sanofi-Aventis Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
|
DE10142666A1
(en)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Use of C2-substituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity
|
DE10142663B4
(en)
|
2001-08-31 |
2004-08-19 |
Aventis Pharma Deutschland Gmbh |
C2-Disubstituted indan-1-ol systems
|
DE10142662B4
(en)
|
2001-08-31 |
2004-07-08 |
Aventis Pharma Deutschland Gmbh |
Derivatives of C2-substituted indan-1-ol systems and their use as pharmaceuticals
|
DE10142659A1
(en)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Use of multiply substituted indan-1-ol. Systems for the preparation of medicaments for the prophylaxis or treatment of obesity
|
DE10142668A1
(en)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Use of C2-substituted indan-1-one systems for the preparation of medicaments for the prophylaxis or treatment of obesity
|
US6884812B2
(en)
|
2001-08-31 |
2005-04-26 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
|
EP2243776A1
(en)
|
2001-10-12 |
2010-10-27 |
High Point Pharmaceuticals, LLC |
Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
|
AU2002365289A1
(en)
*
|
2001-11-30 |
2003-06-10 |
Novo Nordisk A/S |
Use of selective potassium channel openers
|
AU2002342600A1
(en)
*
|
2001-11-30 |
2003-06-10 |
Novo Nordisk A/S |
Use of selective potassium channel openers
|
JP2005518391A
(en)
|
2001-12-21 |
2005-06-23 |
ノボ ノルディスク アクティーゼルスカブ |
Amide derivatives as GK activators
|
US7078404B2
(en)
|
2002-04-11 |
2006-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7223796B2
(en)
|
2002-04-11 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7049341B2
(en)
|
2002-06-07 |
2006-05-23 |
Aventis Pharma Deutschland Gmbh |
N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
|
AU2003232171A1
(en)
*
|
2002-06-14 |
2003-12-31 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a beta cell resting compound
|
US7671047B2
(en)
|
2002-06-19 |
2010-03-02 |
Sanofi-Aventis Deutschland Gmbh |
Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7176194B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7176193B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
MXPA05000130A
(en)
|
2002-06-27 |
2005-02-17 |
Novo Nordisk As |
Aryl carbonyl derivatives as therapeutic agents.
|
DE10231370B4
(en)
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophene glycoside derivatives, medicaments containing these compounds and methods of making these medicaments
|
US7262220B2
(en)
|
2002-07-11 |
2007-08-28 |
Sanofi-Aventis Deutschland Gmbh |
Urea- and urethane-substituted acylureas, process for their preparation and their use
|
MXPA05000053A
(en)
|
2002-07-12 |
2005-04-08 |
Aventis Pharma Gmbh |
Heterocyclically substituted benzoylureas, method for their production and their use as medicaments.
|
US7141561B2
(en)
|
2002-07-25 |
2006-11-28 |
Sanofi-Aventis Deutschland Gmbh |
Substituted diaryl heterocycles, process for their preparation and their use as medicaments
|
US20040157922A1
(en)
|
2002-10-04 |
2004-08-12 |
Aventis Pharma Deutschland Gmbh |
Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
|
US7208504B2
(en)
|
2002-10-12 |
2007-04-24 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic inhibitors of hormone sensitive lipase
|
DE10258007B4
(en)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatic fluoroglycoside derivatives, medicaments containing these compounds and methods for the preparation of these medicaments
|
US20040242583A1
(en)
|
2003-01-20 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
|
US7179941B2
(en)
|
2003-01-23 |
2007-02-20 |
Sanofi-Aventis Deutschland Gmbh |
Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
|
US7652007B2
(en)
|
2003-02-13 |
2010-01-26 |
Sanofi-Aventis Deutschland Gmbh |
Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
|
US7390814B2
(en)
|
2003-02-13 |
2008-06-24 |
Sanofi-Aventis Deutschland Gmbh |
Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
|
DE10306250A1
(en)
|
2003-02-14 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals
|
DE10308355A1
(en)
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl-substituted alkanoic acid derivatives, process for their preparation and their use as medicaments
|
US7148246B2
(en)
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
DE10308353A1
(en)
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as medicines
|
DE10308352A1
(en)
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Branched side chain arylcycloalkyl derivatives, process for their preparation and their use as medicaments
|
DE10308351A1
(en)
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituted cycloalkyl derivatives having acidic, usually heterocyclic groups, processes for their preparation and their use as medicaments
|
US7501440B2
(en)
|
2003-03-07 |
2009-03-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
|
DE10314610A1
(en)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
New diphenylazetidinone with improved physiological properties, process for its preparation, medicaments containing these compounds and its use
|
JP4629657B2
(en)
|
2003-04-11 |
2011-02-09 |
ハイ・ポイント・ファーマスーティカルズ、エルエルシー |
11β-hydroxysteroid dehydrogenase type 1 active compound
|
FR2854634B1
(en)
*
|
2003-05-05 |
2005-07-08 |
Servier Lab |
NOVEL THIADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(en)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituted benzoylureido-o-benzoylamides, process for their preparation and their use
|
EP1670815A2
(en)
|
2003-09-30 |
2006-06-21 |
Novo Nordisk A/S |
Melanocortin receptor agonists
|
ATE498404T1
(en)
|
2003-12-09 |
2011-03-15 |
Novo Nordisk As |
REGULATION OF FOOD PREFERENCE WITH GLP-1 AGONISTS
|
WO2005066145A1
(en)
|
2004-01-06 |
2005-07-21 |
Novo Nordisk A/S |
Heteroaryl-ureas and their use as glucokinase activators
|
US7241787B2
(en)
|
2004-01-25 |
2007-07-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
|
US7470706B2
(en)
|
2004-01-31 |
2008-12-30 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7402674B2
(en)
|
2004-01-31 |
2008-07-22 |
Sanofi-Aventis Deutschland Gmbh, |
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7498341B2
(en)
|
2004-01-31 |
2009-03-03 |
Sanofi Aventis Deutschland Gmbh |
Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
DE102004005172A1
(en)
|
2004-02-02 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Indazole derivatives as inhibitors of the hormone sensitive lipase
|
GT200500063A
(en)
|
2004-04-01 |
2005-10-14 |
|
METHOD FOR TREATMENT OF SCHIZOPHRENIA AND / OR GLUCOREGULATORY ABNORMALITIES
|
DE602004004631D1
(en)
|
2004-04-01 |
2007-03-22 |
Sanofi Aventis Deutschland |
Oxadiazolones, process for their preparation and their use as pharmaceuticals
|
EP1604988A1
(en)
|
2004-05-18 |
2005-12-14 |
Sanofi-Aventis Deutschland GmbH |
Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
|
WO2005120492A1
(en)
|
2004-06-11 |
2005-12-22 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
EP1841749A1
(en)
|
2004-09-02 |
2007-10-10 |
Metabasis Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
DE102004042607A1
(en)
|
2004-09-03 |
2006-03-09 |
Bayer Healthcare Ag |
Substituted phenylaminothiazoles and their use
|
US8263551B2
(en)
|
2004-11-22 |
2012-09-11 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations with a protamine salt
|
CN101137631A
(en)
|
2004-12-03 |
2008-03-05 |
转化技术制药公司 |
Heteroaromatic glucokinase activators
|
US8067362B2
(en)
|
2005-02-02 |
2011-11-29 |
Novo Nordisk As |
Insulin derivatives
|
EP2292653B1
(en)
|
2005-02-02 |
2014-05-21 |
Novo Nordisk A/S |
Novel insulin derivatives
|
DE102005026762A1
(en)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
|
RU2412935C2
(en)
|
2005-06-30 |
2011-02-27 |
Хай Пойнт Фармасьютикалс, ЛЛС |
Phenoxyacetic acids as activators of delta receptors ppar
|
CA2614116A1
(en)
|
2005-07-04 |
2007-01-11 |
Novo Nordisk A/S |
Novel medicaments
|
CN101263131B
(en)
|
2005-07-14 |
2013-04-24 |
特兰斯特克药品公司 |
Urea glucokinase activators
|
WO2007009462A2
(en)
*
|
2005-07-15 |
2007-01-25 |
Region Hovedstaden V/Glostrup Hospital |
Treatment of migraine and headaches
|
ES2426345T3
(en)
|
2005-07-20 |
2013-10-22 |
Eli Lilly And Company |
Compound bound in 1-amino position
|
CA2629223C
(en)
|
2005-11-17 |
2013-08-06 |
Eli Lilly And Company |
Glucagon receptor antagonists, preparation and therapeutic uses
|
EP2386540A1
(en)
|
2005-12-22 |
2011-11-16 |
High Point Pharmaceuticals, LLC |
Novel compounds, their preparation and use
|
CN101443314B
(en)
|
2006-03-13 |
2014-04-09 |
杏林制药株式会社 |
Aminoquinolones as GSK-3 inhibitors
|
WO2007110364A1
(en)
|
2006-03-28 |
2007-10-04 |
High Point Pharmaceuticals, Llc |
Benzothiazoles having histamine h3 receptor activity
|
CN102295606A
(en)
|
2006-05-29 |
2011-12-28 |
高点制药有限责任公司 |
Method of combining 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine,and applicable intermediates thereof its salts and solvates and its use as histamine h3 receptor antagonist
|
DE102006028862A1
(en)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-amino-imidazo [1,2-a] pyridine
|
EP2061767B1
(en)
|
2006-08-08 |
2014-12-17 |
Sanofi |
Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
|
DE102006042143A1
(en)
|
2006-09-08 |
2008-03-27 |
Bayer Healthcare Aktiengesellschaft |
Novel substituted bipyridine derivatives and their use
|
EP2086951B1
(en)
|
2006-11-15 |
2011-12-21 |
High Point Pharmaceuticals, LLC |
Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
|
DE102006056739A1
(en)
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Substituted 4-amino-3,5-dicyano-2-thiopyridines and their use
|
DE102006056740A1
(en)
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Cyclic substituted 3,5-dicyano-2-thiopyridines and their use
|
WO2008084044A1
(en)
|
2007-01-11 |
2008-07-17 |
Novo Nordisk A/S |
Urea glucokinase activators
|
DE102007002260A1
(en)
|
2007-01-16 |
2008-07-31 |
Sanofi-Aventis |
Use of substituted pyranonic acid derivatives for the preparation of medicaments for the treatment of the metabolic syndrome
|
DE102007005045B4
(en)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazine derivatives, process for their preparation and their use as medicines
|
DE102007008420A1
(en)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
benzimidazole derivatives
|
US20080319221A1
(en)
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
DE102007035367A1
(en)
|
2007-07-27 |
2009-01-29 |
Bayer Healthcare Ag |
Substituted aryloxazoles and their use
|
DE102007036076A1
(en)
|
2007-08-01 |
2009-02-05 |
Bayer Healthcare Aktiengesellschaft |
Dipeptoid Produgs and their use
|
EP2025674A1
(en)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
|
DE102007042754A1
(en)
|
2007-09-07 |
2009-03-12 |
Bayer Healthcare Ag |
Substituted 6-phenyl-nicotinic acids and their use
|
JP5426552B2
(en)
|
2007-09-11 |
2014-02-26 |
杏林製薬株式会社 |
Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
|
MX2010002662A
(en)
|
2007-09-12 |
2010-04-09 |
Activx Biosciences Inc |
Spirocyclic aminoquinolones as gsk-3 inhibitors.
|
DE102007048716A1
(en)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo [1,2-a] pyrimidine derivatives
|
DE102007063671A1
(en)
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
New crystalline diphenylazetidinone hydrates, medicaments containing these compounds and their use
|
DE102007061763A1
(en)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituted azabicyclic compounds and their use
|
DE102007061757A1
(en)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituted 2-phenylpyrimidine-5-carboxylic acids and their use
|
DE102007061764A1
(en)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Anellated cyanopyridines and their use
|
DE102007061756A1
(en)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituted 4-aminopyrimidine-5-carboxylic acids and their use
|
DE102008008838A1
(en)
|
2008-02-13 |
2009-08-20 |
Bayer Healthcare Ag |
Cycloalkoxy-substituted 4-phenyl-3,5-dicyanopyridines and their use
|
DE102008013587A1
(en)
|
2008-03-11 |
2009-09-17 |
Bayer Schering Pharma Aktiengesellschaft |
Heteroaryl-substituted dicyanopyridines and their use
|
DE102008017590A1
(en)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
CN101555214B
(en)
|
2008-04-08 |
2012-07-11 |
北京嘉事联博医药科技有限公司 |
Phenylcyclobutylacylamide derivative as well as optical isomer, preparation method and application thereof
|
WO2009143992A1
(en)
|
2008-05-29 |
2009-12-03 |
Bayer Schering Pharma Aktiengesellschaft |
2-alkoxy-substituted dicyanopyridines and use thereof
|
WO2010003624A2
(en)
|
2008-07-09 |
2010-01-14 |
Sanofi-Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
US8927549B2
(en)
|
2008-11-21 |
2015-01-06 |
High Point Pharmaceuticals, Llc |
Adamantyl benzamide derivatives
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
DE102008062567A1
(en)
|
2008-12-16 |
2010-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Dipeptoid prodrugs and their use
|
DE102008062566A1
(en)
|
2008-12-16 |
2010-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Amino acid ester prodrugs and their use
|
DE102009006602A1
(en)
|
2009-01-29 |
2010-08-05 |
Bayer Schering Pharma Aktiengesellschaft |
Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
|
CN102482312A
(en)
|
2009-08-26 |
2012-05-30 |
赛诺菲 |
Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
|
WO2011039338A2
(en)
|
2009-10-02 |
2011-04-07 |
Sanofi-Aventis |
Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
|
US20130012432A1
(en)
|
2010-02-26 |
2013-01-10 |
Novo Nordisk A/S |
Peptides for Treatment of Obesity
|
BR112012021231A2
(en)
|
2010-02-26 |
2015-09-08 |
Basf Plant Science Co Gmbh |
method for enhancing plant yield, plant, construct, use of a construct, method for producing a transgenic plant, collectable parts of a plant, products derived from a plant, use of a nucleic acid and method for producing a product
|
WO2011107494A1
(en)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
|
JP6054861B2
(en)
|
2010-03-26 |
2016-12-27 |
ノヴォ ノルディスク アー/エス |
New glucagon analogues
|
DE102010015123A1
(en)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
CA2803688A1
(en)
|
2010-06-25 |
2011-12-29 |
Bayer Intellectual Property Gmbh |
Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
|
DE102010030688A1
(en)
|
2010-06-30 |
2012-01-05 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted dicyanopyridines and their use
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
US20120058983A1
(en)
|
2010-09-02 |
2012-03-08 |
Bayer Pharma Aktiengesellschaft |
Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
|
WO2012120053A1
(en)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
EP2683702B1
(en)
|
2011-03-08 |
2014-12-24 |
Sanofi |
New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
|
WO2012120058A1
(en)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
WO2012120056A1
(en)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
WO2012120054A1
(en)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
EP2683698B1
(en)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
|
US8901114B2
(en)
|
2011-03-08 |
2014-12-02 |
Sanofi |
Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
|
WO2012120055A1
(en)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
EP2683703B1
(en)
|
2011-03-08 |
2015-05-27 |
Sanofi |
Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
BR112013024076A2
(en)
|
2011-03-28 |
2016-12-06 |
Novo Nordisk As |
glucagon analogs
|
CN103930440A
(en)
|
2011-07-01 |
2014-07-16 |
拜耳知识产权有限责任公司 |
Relaxin fusion polypeptides and uses thereof
|
WO2013007563A1
(en)
|
2011-07-08 |
2013-01-17 |
Bayer Intellectual Property Gmbh |
Fusion proteins releasing relaxin and uses thereof
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
TWI596110B
(en)
|
2011-09-23 |
2017-08-21 |
諾佛 儂迪克股份有限公司 |
Novel glucagon analogues
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013144191A1
(en)
|
2012-03-29 |
2013-10-03 |
Bayer Intellectual Property Gmbh |
Substituted 2-amino-3-cyanopyridines as inhibitors of sodium-calcium exchange and use thereof for cardiovascular diseases
|
US9867869B2
(en)
|
2012-12-12 |
2018-01-16 |
Massachusetts Institute Of Technology |
Insulin derivatives for diabetes treatment
|
AU2014255608B2
(en)
|
2013-04-18 |
2018-01-25 |
Novo Nordisk A/S |
Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
|
ES2708577T3
(en)
|
2013-09-04 |
2019-04-10 |
Univ Kyoto |
Medicinal composition that improves the resistance to leptin
|
JOP20200052A1
(en)
|
2013-12-19 |
2017-06-16 |
Bayer Pharma AG |
Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
|
AP2016009303A0
(en)
|
2013-12-19 |
2016-06-30 |
Bayer Pharma AG |
Substituted piperidinyl-tetrahydroquinolines
|
JP2017503783A
(en)
|
2013-12-19 |
2017-02-02 |
バイエル ファーマ アクチエンゲゼルシャフト |
Substituted bipiperidinyl derivatives as adrenergic receptor alpha 2C antagonists
|
WO2015091420A1
(en)
|
2013-12-19 |
2015-06-25 |
Bayer Pharma Aktiengesellschaft |
Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists
|
CN106536547A
(en)
|
2014-06-04 |
2017-03-22 |
诺和诺德股份有限公司 |
GLP-1/glucagon receptor co-agonists for medical use
|
US20190008867A1
(en)
|
2015-11-13 |
2019-01-10 |
Ph Pharma Co., Ltd. |
4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
|
MA49883A
(en)
|
2017-03-15 |
2021-04-21 |
Novo Nordisk As |
BICYCLIC COMPOUNDS SUITABLE TO BIND TO MELANOCORTIN 4 RECEPTOR
|
US20210221867A1
(en)
|
2018-05-15 |
2021-07-22 |
Novo Nordisk A/S |
Compounds Capable of Binding to Melanocortin 4 Receptor
|
WO2020053414A1
(en)
|
2018-09-14 |
2020-03-19 |
Novo Nordisk A/S |
Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
|
WO2020165031A1
(en)
|
2019-02-15 |
2020-08-20 |
Bayer Aktiengesellschaft |
Substituted isoquinoline-piperidinylmethanone derivatives
|